Clinical Trials

Patients

Clinical Trials

Our clinical trials help to advance the understanding of innovative medicines and determine whether the new treatments are being developed are safe and effective.

We know that the decision to participate in clinical trial research is not made lightly, and we sincerely thank all the patients and families who choose to partake. Your physician is the best person to help you decide if a clinical trial or any other treatment option is right for you.

The agents listed below are currently under investigation. Their safety and effectiveness have not yet been established.

ARV-471

ARV-471 is an investigational orally bioavailable PROTAC® protein degrader designed to target and degrade the estrogen receptor (ER) for the treatment of patients with locally advanced or metastatic ER-positive / HER2-negative breast cancer.

ARV-471 is an investigational compound. It’s safety and efficacy has not been established.

Currently Recruiting:

ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer (NCT05501769)

A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (NCT04072952)

If you’re interested in learning more about this trial, please speak with your doctor and visit the website www.clinicaltrials.gov

Collaborator:

Bavdegalutamide (ARV-110)

Bavdegalutamide (ARV-110) is an investigational orally bioavailable PROTAC® protein degrader designed to selectively target and degrade the androgen receptor (AR). Bavdegalutamide is being developed as a potential treatment for men with metastatic castration-resistant prostate cancer (mCRPC).

Currently Recruiting:

Trial of ARV-110 and Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (NCT05177042)

Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (NCT03888612)

If you’re interested in learning more about this trial, please speak with your doctor and visit the website www.clinicaltrials.gov

ARV-766

ARV-766 is an investigational orally bioavailable PROTAC® protein degrader designed to selectively target and degrade the androgen receptor (AR). ARV-766 is being developed as a potential treatment for men with metastatic castration-resistant prostate cancer (mCRPC).

Currently Recruiting:

Clinical Trial to Evaluate ARV-766 in Patients With Metastatic Castration-Resistant Prostate Cancer (NCT05067140)

If you’re interested in learning more about this trial, please speak with your doctor and visit the website www.clinicaltrials.gov